CAI Stock Analysis: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$16.99
-0.88 (-4.92%)
▼
5d:
-7.16%
30d:
+0.18%
90d:
-11.51%
HOLD
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 11, 2026
28d
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CAI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CAI shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.80
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.05
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $16.99, which is considered slightly low relative to its 30-day fair value range of $16.76 to $18.37. The stock's valuation (Forward PE: 46.5) is in line with its historical norms (48.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CAI is in a downtrend. The price is currently testing key support at $16.73. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.42 (+61.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CAI is in a downtrend. The price is currently testing key support at $16.73. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $27.42 (+61.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$16.76 -
$18.37
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 61.4% below Wall St target ($27.42)
- CAUTION: Recommendation downgraded due to -7.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$16.76 -
$18.37
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$16.73
Resistance Level
$19.97
Current Trend
Downtrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
46.46
Wall Street Target
$27.42
(+61.4%)
Revenue Growth (YoY)
78.8%
Profit Margin
3.8%
Valuation Discount vs History
-1.6% cheaper
PE vs Historical
46.5 vs 48.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.6%
(market-implied from PE analysis)
1-Year Target
$16.72
(-2%)
2-Year Target
$16.45
(-3%)
3-Year Target
$16.19
(-5%)
3-Yr Target (if PE normalizes)
(PE: 46→49)
$16.97
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 46.5, Growth: 175.2%)
$57.34
(+238%)
Base:
(SPY PE: 21.8, Growth: 175.2%)
$26.88
(+58%)
Bear:
(PE: 18.5, Growth: 175.2%)
$22.85
(+35%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 46.5 to 48.7
Stabilization Target:
$17.81
(+4.8%)
PE Expansion Potential:
+4.8%
Share & Embed Analysis
Last updated: July 13, 2026 9:19 AM ET
Data refreshes hourly during market hours. Next update: 10:19 AM
Data refreshes hourly during market hours. Next update: 10:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 62 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 56 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 63 BUY |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$200 | 65 BUY |